An interventional study of Single anastomosis sleeve ileal bypass and Sleeve gastrectomy in Obesity, Morbid, sponsored by Oslo University Hospital. Recruiting at 2 sites in Norway. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-18.
Sponsored by Oslo University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Obesity, Morbid with a site in Norway — 22 open to participants now, 26 under way, none of them phase 3. Obesity, Morbid · Norway.
Among the 51 studies in Obesity, Morbid with a site in Norway, this one is the 2nd largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2023, is one of 18 with no phase, reaches primary completion later than 24 of the 25 other live ones, and was the 51st registered.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
Browse Obesity, Morbid studies →22 of the 51 studies in Obesity, Morbid with a site in Norway are open now. Recruiting first, the newest first:
Norwegian University of Science and Technology · Sites in Norway
Ages 18–70
Norwegian University of Science and Technology · Sites in Norway
Ages 18–70
Norwegian University of Science and Technology · Sites in Norway
Ages 18–70
Norwegian University of Science and Technology · Sites in Norway
Ages 18–70
Norwegian University of Science and Technology · Sites in Norway
Ages 18–70
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 20 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 220 is above the median of 62 across 601 interventional studies indexed under Obesity, Morbid.
Median enrollment 69 across the 21 interventional studies, 12 across the 30 observational. Of the 23 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 51 has an industry lead sponsor. The 10 most frequent:
Oslo University Hospital is the lead sponsor of 835 studies on the registry; 148 are open to participants now.
Oslo University Hospital has 4 studies filed under Obesity, Morbid — fewer than ten, so there is no comparison to draw.
6 of the studies in Obesity, Morbid with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00626964The Hospital of VestfoldPrevention of Coronary Heart Disease in Morbidly Obese Patients | 2026-12 |
| NCT02767505Göteborg UniversityBypass Equipoise Sleeve Trial (BEST) | 2026-12 |
| NCT03448783Norwegian University of Science and TechnologyBariatric Surgery and Pharmacokinetics of Apixaban | 2026-12 |
| NCT03440177Norwegian University of Science and TechnologyBariatric Surgery and Pharmacokinetics of Ramipril | 2026-12 |
| NCT03449485Norwegian University of Science and TechnologyBariatric Surgery and Pharmacokinetics of Chlorprothixene | 2026-12 |
Add all 6 to your calendar (.ics) → With an account.
Among the 51 studies in Obesity, Morbid with a site in Norway, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will compare two bariatric surgical interventions in terms of weight loss, gastroesophageal reflux, and effects on obesity-related comorbid conditions in morbidly obese patients.
Sleeve gastrectomy is an established therapeutic option for morbidly obese patients without preexisting gastroesophageal reflux disease. The novel single anastomosis sleeve ileal bypass (SASI) procedure is already introduced in Norway at a private high-volume bariatric hospital. The purpose of this study is to evaluate the effects of SASI in comparison to an established bariatric procedure, i.e. sleeve gastrectomy. The primary end point is 2-year changes in BMI after sleeve gastrectomy and SASI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A Single anastomosis sleeve ileal bypass procedure is performed.
Procedure: Single anastomosis sleeve ileal bypass
A sleeve gastrectomy procedure is performed.
Procedure: Sleeve gastrectomy
The abdominal cavity is entered directly (visual trocar) with or without the use of Verres needle. A 6-port set up and a liver retractor is utilized. A sleeve gastrectomy is performed as described below, but division of the stomach starts 6 cm proximal to the pylorus. The small bowel is measured 300cm from the ileocecal valve, with the small bowel stretched and markers placed on the graspers, and connected to the antrum of the stomach with a 45mm stapler. The anastomosis is positioned slightly ventral on the antrum. A 12 mm port positioned left to the midline is used for introduction of the stapler, which is directed distally from the patient's left to right side. 3.0 cm of 45 mm stapler is used the anastomosis; completed with a 2-0 PDS running suture. The biliopancreatic limb is anchored to the sleeve 4 cm proximal to the anastomosis (non-resorbable V-loc 3-0). Fascia defect is closed for the port where the specimen is extracted. The mesenteric defect is not closed.
Also known as: SASI
In the laparoscopic sleeve gastrectomy, the abdominal cavity is entered directly with a visual trocar with or without the use of Verres needle. The set up includes a total of 5 ports. The Natanson liver retractor is utilized. The greater omentum is separated from the major side of the stomach from the pylorus to the angle of His. The left crus is visualized and the hiatus is inspected for the presence of hernia. A 36 French bougie is introduced and the stomach is divided along this from 4-5cm proximal to the pylorus to 1cm lateral to the angle of His using two purple cartridges (Medtronic Tri-Staple™ technology) followed by beige 60mm cartridges to the angle of His, 1 cm lateral to the esophagus. The sleeve is tested for leaks with instillation of 50ml methylene blue in the tube. The fascia defect is closed with suture for the port site where the specimen is extracted.
Changes in body-mass index (BMI)
Weight in kilograms divided by the square of the height in meters after sleeve gastrectomy and SASI.
Time frame: 2 year
Change in prevalence of esophagitis.
Changes in the prevalence of esophagitis as evaluated by upper endoscopy.
Time frame: 2 year
Change in prevalence of gastroesophageal reflux disease.
Changes in the prevalence of gastroesophageal reflux disease as evaluated by 24-hour pH measurements.
Time frame: 2 year
Complications
Complications during surgery, postoperative complications (within 6 weeks \[100 days for deaths\]) as defined by the Accordion severity grading system and long-term complications.
Time frame: 6 weeks (100 days for deaths), 2 year, 5 year
Obesity-related comorbid conditions.
Changes in obesity-related comorbid conditions.
Time frame: 2 year, 5 year
Vitamin concentrations
Changes in vitamin levels (A, B1, B6, B9, B12, C, D, K).
Time frame: 2 year, 5 year
Health-related quality of life
The RAND 36-Item Short Form Health Survery is a self-reporting questionnaire. Items are scored from 0 (lowest score) to 100 (highest possible score).
Time frame: 2 year, 5 year
Obesity-related symptoms
Obesity-related Problem scale
Time frame: 2 year, 5 year
Gastrointestinal symptoms
GSRS
Time frame: 2 year, 5 year
Gastroesophageal reflux disease symptoms
GERDq
Time frame: 2 year, 5 year
Bowel habits
Bowel habit questionnaire
Time frame: 2 year, 5 year
Revisional surgery
Revisional surgery rates in the two groups.
Time frame: 2 year, 5 year
Long-term changes in BMI
BMI (weight in kilograms divided by the square of the height in meters) after sleeve gastrectomy and SASI.
Time frame: 5 years
Body composition
Changes in percentage fat mass and lean mass; percentage change in bone mineral density in lumbar spine (L1-L4), femoral neck, and total hip as assessed by DEXA scan.
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2023 (actual). Primary completion is estimated for Dec 2028, 70 months after the start.
Of 273 non-industry interventional studies with no phase under Obesity, Morbid, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 70 months is above that.
Counting every sponsor, half of 285 studies reached it within 25 months; a quarter within 11 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.